Relief Therapeutics Holding Stock Price To Sales
| RLFTF Stock | USD 5.69 0.09 1.61% |
Relief Therapeutics Holding fundamentals help investors to digest information that contributes to Relief Therapeutics' financial success or failures. It also enables traders to predict the movement of Relief OTC Stock. The fundamental analysis module provides a way to measure Relief Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Relief Therapeutics otc stock.
Relief |
Relief Therapeutics Holding OTC Stock Price To Sales Analysis
Relief Therapeutics' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Relief Therapeutics Price To Sales | 22.16 X |
Most of Relief Therapeutics' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Relief Therapeutics Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Relief Therapeutics Holding has a Price To Sales of 22.1607 times. This is 3.55% higher than that of the Healthcare sector and 77.48% lower than that of the Biotechnology industry. The price to sales for all United States stocks is 94.05% lower than that of the firm.
Relief Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Relief Therapeutics' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Relief Therapeutics could also be used in its relative valuation, which is a method of valuing Relief Therapeutics by comparing valuation metrics of similar companies.Relief Therapeutics is currently under evaluation in price to sales category among its peers.
Relief Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Relief Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Relief Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Relief Fundamentals
| Return On Equity | -0.33 | |||
| Return On Asset | -0.12 | |||
| Operating Margin | (5.96) % | |||
| Current Valuation | 102.36 M | |||
| Shares Outstanding | 4.39 B | |||
| Shares Owned By Insiders | 3.68 % | |||
| Shares Owned By Institutions | 22.16 % | |||
| Price To Book | 0.70 X | |||
| Price To Sales | 22.16 X | |||
| Revenue | 3.32 M | |||
| Gross Profit | 2.57 M | |||
| EBITDA | (33.3 M) | |||
| Net Income | (34.7 M) | |||
| Cash And Equivalents | 29.87 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 396 K | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 2.80 X | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (35.72 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 10 | |||
| Beta | -13.71 | |||
| Market Capitalization | 120.99 M | |||
| Total Asset | 251.62 M | |||
| Net Asset | 251.62 M |
About Relief Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Relief Therapeutics Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Relief Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Relief Therapeutics Holding based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Relief OTC Stock
Relief Therapeutics financial ratios help investors to determine whether Relief OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Relief with respect to the benefits of owning Relief Therapeutics security.